Early Adoption and Partnerships – The Secret to Commercialization Success?
2 March 2023
Collaborations, Mergers & Acquisitions
This Briefing from Advanced Therapies Week 2023 focusses on how partnerships within the industry can advance research from the clinic to manufacturing scale, to keep pace with the evolving field.
During this session, Terumo’s Stuart Gibb, PhD, Scientific Strategy Lead at Terumo Blood and Cell Technologies, is joined by Nisha C. Durand, PhD, Principal Research Technologist at Mayo Clinic and Matthew M. Hewitt, B.A. PhD, Executive Director, Scientific Services Cell and Gene Therapy at Charles River.
This Briefing was presented at Advanced Therapies Week 2023, in partnership with Terumo.
More like this
Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers
Kite’s Yescarta CAR-T cell therapy has demonstrated significant improvement for the treatment of relapsed/refractory large B-cell lymphoma from its Phase III ZUMA trial.
23 March 2023
Pfizer Invests $43 Billion to Acquire Seagen
Pfizer is to acquire global technology company Seagan in a definitive merger agreement for a total enterprise value of $43 billion.
14 March 2023
Autologous vs Allogeneic: What Therapeutic Developers and Manufacturers Really Need to Know
Rupa Pike, Senior Director of Technical Affairs, Advanced Therapies, Thermo Fisher Scientific, joined us live at Advanced Therapies Week 2023 to discuss and shed some light on the current autologous vs allogeneic cell therapy landscape.
16 March 2023